SCHEMBL3452274

SCHEMBL3452274

CCOCC(NC(=O)Nc1ccc(Cl)cc1)C(=O)N1CCN(N2Cc3cnc(C)n3C2=O)CC1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
F10 P00742 6/20 0.46
F2 P00734 1/20 0.36
ALDH1A1 P00352 2/20 0.36
CCKBR P32239 3/20 0.36
UGCG Q16739 4/20 0.35
P2RY12 Q9H244 1/20 0.35
FPR2 P25090 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
HTT P42858 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13123318 0.92 F10 (0.39) F10CCKBRFPR2
SCHEMBL3450125 0.92 F10 (0.47) F10F2ALDH1A1CCKBRCHRM2
SCHEMBL14541600 0.92 F10 (0.39) F10CCKBRFPR2CHRM2CHRM3
SCHEMBL3449172 0.88 F10 (0.46) F10F2ALDH1A1CCKBRP2RY12
SCHEMBL13108401 0.88 F10 (0.46) F10F2ALDH1A1CCKBRP2RY12
SCHEMBL3448772 0.86 FPR2 (0.49) F10ALDH1A1UGCGFPR2CHRM2
SCHEMBL3450519 0.86 FPR2 (0.49) F10ALDH1A1UGCGFPR2CHRM2
SCHEMBL3449574 0.86 F10 (0.46) F10F2ALDH1A1CCKBRFPR2
SCHEMBL3451657 0.85 F10 (0.45) F10ALDH1A1FPR2CHRM2CHRM1
SCHEMBL3450203 0.85 F10 (0.48) F10F2ALDH1A1CCKBRP2RY12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820673-B2 Urea derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-26 US disclosed
US-7820673-B2 Urea derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-26 US disclosed
US-20070093501-A1 Urea derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-04-26 US disclosed
US-20070093501-A1 Urea derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-04-26 US disclosed
EP-1695961-A1 UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2006-08-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093501-A1 Urea derivative, process for producing the same, and use F2, URB2, F12 F10 22/4885F2 1/4885ALDH1A1 3712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.